Jacob Asset Management of New York’s DiaMedica Therapeutics DMAC Stock Holding History

Jacob Asset Management of New York’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$435K	Sell	168,730 -30,000	-15%	-$96.4K	0.61%	45
2023 Q2	$859K	Sell	198,730 -35,000	-15%	-$85K	0.97%	38
2023 Q1	$358K	Hold	233,730	–	–	0.42%	49
2022 Q4	$369K	Sell	233,730 -4,770	-2%	-$6.42K	0.45%	49
2022 Q3	$296K	Hold	238,500	–	–	0.32%	50
2022 Q2	$482K	Sell	238,500 -26,500	-10%	-$61.8K	0.49%	45
2022 Q1	$663K	Sell	265,000 -10,000	-4%	-$28.4K	0.4%	50
2021 Q4	$1.03M	Hold	275,000	–	–	0.46%	49
2021 Q3	$1.1M	Hold	275,000	–	–	0.4%	52
2021 Q2	$1.22M	Buy	275,000 +90,000	+49%	+$738K	0.4%	56
2021 Q1	$1.69M	Buy	185,000 +45,000	+32%	+$420K	0.66%	43
2020 Q4	$1.42M	Buy	+140,000	New	+$766K	1.07%	29

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacob Asset Management of New York's DMAC Position: Q3 2023 in Review

Jacob Asset Management of New York reduced its DiaMedica Therapeutics (DMAC) stake by 15% in Q3 2023, selling an estimated $96.4K and leaving 168,730 shares worth $435K. The position accounts for 0.61% of the portfolio, ranked #45.

Jacob Asset Management of New York first reported a position in DMAC in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.69M in Q1 2021. 36 funds tracked by Wall St. Rank hold DMAC as of Q3 2023.

Jacob Asset Management of New York held 168,730 shares of DiaMedica Therapeutics worth $435K as of Q3 2023.
Jacob Asset Management of New York sold 30,000 DiaMedica Therapeutics shares in Q3 2023, an estimated $96.4K.
DiaMedica Therapeutics made up 0.61% of Jacob Asset Management of New York's portfolio in Q3 2023, its #45 holding.
Jacob Asset Management of New York first reported a position in DiaMedica Therapeutics in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's DiaMedica Therapeutics position peaked at $1.69M in Q1 2021.
36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.